Q4 2019

Filed Mar 19, 2020 · 10-K · 79 days after period end · 0001787306-20-000005

Q4 2019 · 10-K

Revenue—

Net Income

-$12.57M

no prior Q4 2018 on file

EPS Diluted

-$6.13

no prior Q4 2018 on file

Operating Incomederived-$12,994,000—

Same quarter

no prior Q4 2018 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Dec 31, 2019 · filed Mar 19, 2020 · 79 d after period end

Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR